Just reported
From Illumina's results release of 29 octombrie 2026; its quarterly report has since been filed.
Actual
1,13B USD
+4,2 % y/y
-2,6 % q/q
Guided
—
No guide given
Actual
1,43 USD
+46 % y/y
+5,9 % q/q
Guided
—
No guide given
Actual
305M USD
+34 % y/y
+24 % q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Ponderile din venituri sunt estimări pentru quarter ended 2026-03-31, nu cifre dintr-un raport depus.
NovaSeq X
A high-throughput DNA-sequencing machine used by customers that need to process large numbers of samples.
MiSeq i100
A lower-throughput DNA-sequencing machine for labs running smaller or more project-based batches.
NovaSeq 6000
A high-throughput DNA-sequencing machine that some customers continue to use alongside newer systems.
StrataMap Spatial
A sequencing-based workflow that helps researchers study biological activity in specific locations within tissue.
SomaScan and SomaSeq
Tools for measuring proteins and connecting protein measurements with genetic information.
Billion Cell Atlas
A large collection of data on how cells respond to genetic changes, sold to drug companies for biological research and drug discovery.
Situațiile financiare complete →
Illumina makes machines that read DNA and sells the chemicals and other supplies customers use to run samples on them. Hospitals and clinical laboratories use sequencing for applications such as cancer testing, inherited-disease testing and screening; researchers and drug companies use it to study biology and develop medicines. Illumina also sells tools for measuring proteins and provides biological data and related services.
Construit din raportările proprii ale Illumina, Inc. la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.
209,61 USD-1,5 %închidere 12 nov.
Cifre până la 27 septembrie 2026, din 10-Q depus pe 30 octombrie 2026
Illumina sells DNA-sequencing kits and machines to medical laboratories, hospitals, universities and drug companies.
The themes Illumina is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A+
Banda de sub preț arată nota la fiecare dată, calculată doar din documentele publice până atunci.
Se afișează 2 din 41 trimestre din istoricul notelor companiei Illumina, Inc.. Celelalte 39 merg înapoi până în noiembrie 2016.
